A 2-Year, Open-Label Pilot Study of Adjunctive Chromium in Patients With Treatment-Resistant Rapid-Cycling Bipolar Disorder

Benedikt L. Amann; Roland Mergl; Eduard Vieta; Christoph Born; Igor Hermisson; Florian Seemueller; Sandra Dittmann; Heinz Grunze

doi:10.1097/jcp.0b013e31802e744b

Back

A 2-Year, Open-Label Pilot Study of Adjunctive Chromium in Patients With Treatment-Resistant Rapid-Cycling Bipolar Disorder

Letter 2007 en

Abstract

1 min read

Amann, Benedikt L. MD; Mergl, Roland PhD; Vieta, Eduard MD, PhD; Born, Christoph MD; Hermisson, Igor MD; Seemueller, Florian MD; Dittmann, Sandra MSc; Grunze, Heinz MD Author Information

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Letter2006

An Exploratory Open Trial on Safety and Efficacy of the Anticonvulsant Retigabine in Acute Manic Patients

Benedikt L. Amann, Andrea Sterr, Eduard Vieta, Robert Stampfer, Jörg Walden, Heinz Grunze

Letter2009

Response to Shen J, Kobak K, Zhao Y, et al. Use of Remote Centralized Raters Via Live 2-Way Video in a Multicenter Clinical Trial for Schizophrenia. (J Clin Psychopharmacol. 2008;28:691-693)

Heinz Grunze, Cyril Höschl, Stuart Montgomery, Norman Sartorius, Eduard Vieta

Letter1998

Treatment of Refractory Rapid Cycling Bipolar Disorder With Risperidone

Eduard Vieta, Cristòbal Gastó, Francesc Colom, A. Otero, J. Vallejo

Article1996

Risperidone in the treatment of rapid cycling bipolar disorder

Eduard Vieta, Cristòbal Gastó, A. Otero, J. Vallejo

Article2002

Quetiapine in the treatment of rapid cycling bipolar disorder

Eduard Vieta, Gemma Parramón, Elena Padrell, E. Nieto, Anabel Martínez‐Arán, Bàrbara Corbella, Francesc Colom, María Reinares, José Manuel Goikolea, Carla Torrent